Cargando…
Decline in FEV(1) and hospitalized exacerbations in individuals with severe alpha-1 antitrypsin deficiency
Background and aim: The value of the forced expiratory volume in one second (FEV(1)) is useful in the diagnosis and prognosis of chronic obstructive pulmonary disease (COPD). Previous studies on lung function in individuals with severe alpha-1 antitrypsin deficiency (AATD) have shown a variable annu...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536893/ https://www.ncbi.nlm.nih.gov/pubmed/31213789 http://dx.doi.org/10.2147/COPD.S195847 |
_version_ | 1783421873148657664 |
---|---|
author | Hiller, Adriana-Maria Piitulainen, Eeva Jehpsson, Lars Tanash, Hanan |
author_facet | Hiller, Adriana-Maria Piitulainen, Eeva Jehpsson, Lars Tanash, Hanan |
author_sort | Hiller, Adriana-Maria |
collection | PubMed |
description | Background and aim: The value of the forced expiratory volume in one second (FEV(1)) is useful in the diagnosis and prognosis of chronic obstructive pulmonary disease (COPD). Previous studies on lung function in individuals with severe alpha-1 antitrypsin deficiency (AATD) have shown a variable annual decline in FEV(1) (∆FEV(1)). The aim of this study was to analyze ∆FEV(1) and to identify risk factors for ∆FEV(1) in individuals with severe AATD. Material and methods: Data on smoking habits, symptoms, results of lung function tests and exacerbations were obtained from the Swedish AATD Register and the Swedish National Patient Register (SNPR). The ∆FEV(1) was analyzed by random-effects modeling and adjusted for age and FEV(1) at baseline. Results: One hundred and four (9%) current smokers, 539 (48%) ex-smokers and 489 (43%) never-smokers were included in the study and followed-up from 1991 to 2016. A total of 584 (52%) individuals with severe AATD had COPD at inclusion. The median (IQR) annual severe exacerbation rate was 0.66 (1.4). The adjusted mean ∆FEV(1) was significantly higher in the current smokers compared with the ex-smokers and never-smokers (70 [95% CI 56–83] vs 42 [95% CI 36–48] and 32 [95% CI 25–38) mL·yr(−1)], in the middle–aged individuals compared with the young individuals (48 [95% CI 41–55] vs 32 [95% CI 18–45] mL·yr(−1)), in the individuals with respiratory symptoms at inclusion compared with the asymptomatic individuals (46 [95% CI 40–52] vs 30 [95% CI 22–38]mL·yr(−1)), and in the individuals with frequent exacerbations compared with those with infrequent exacerbations (57 [95% CI 47–68] vs 27 [95% CI 17–37] mL·yr(−1)). Conclusion: Active smoking, age, respiratory symptoms at baseline and repeated severe exacerbations of COPD are factors associated with an accelerated decline of lung function in individuals with severe AATD. |
format | Online Article Text |
id | pubmed-6536893 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-65368932019-06-18 Decline in FEV(1) and hospitalized exacerbations in individuals with severe alpha-1 antitrypsin deficiency Hiller, Adriana-Maria Piitulainen, Eeva Jehpsson, Lars Tanash, Hanan Int J Chron Obstruct Pulmon Dis Original Research Background and aim: The value of the forced expiratory volume in one second (FEV(1)) is useful in the diagnosis and prognosis of chronic obstructive pulmonary disease (COPD). Previous studies on lung function in individuals with severe alpha-1 antitrypsin deficiency (AATD) have shown a variable annual decline in FEV(1) (∆FEV(1)). The aim of this study was to analyze ∆FEV(1) and to identify risk factors for ∆FEV(1) in individuals with severe AATD. Material and methods: Data on smoking habits, symptoms, results of lung function tests and exacerbations were obtained from the Swedish AATD Register and the Swedish National Patient Register (SNPR). The ∆FEV(1) was analyzed by random-effects modeling and adjusted for age and FEV(1) at baseline. Results: One hundred and four (9%) current smokers, 539 (48%) ex-smokers and 489 (43%) never-smokers were included in the study and followed-up from 1991 to 2016. A total of 584 (52%) individuals with severe AATD had COPD at inclusion. The median (IQR) annual severe exacerbation rate was 0.66 (1.4). The adjusted mean ∆FEV(1) was significantly higher in the current smokers compared with the ex-smokers and never-smokers (70 [95% CI 56–83] vs 42 [95% CI 36–48] and 32 [95% CI 25–38) mL·yr(−1)], in the middle–aged individuals compared with the young individuals (48 [95% CI 41–55] vs 32 [95% CI 18–45] mL·yr(−1)), in the individuals with respiratory symptoms at inclusion compared with the asymptomatic individuals (46 [95% CI 40–52] vs 30 [95% CI 22–38]mL·yr(−1)), and in the individuals with frequent exacerbations compared with those with infrequent exacerbations (57 [95% CI 47–68] vs 27 [95% CI 17–37] mL·yr(−1)). Conclusion: Active smoking, age, respiratory symptoms at baseline and repeated severe exacerbations of COPD are factors associated with an accelerated decline of lung function in individuals with severe AATD. Dove 2019-05-23 /pmc/articles/PMC6536893/ /pubmed/31213789 http://dx.doi.org/10.2147/COPD.S195847 Text en © 2019 Hiller et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Hiller, Adriana-Maria Piitulainen, Eeva Jehpsson, Lars Tanash, Hanan Decline in FEV(1) and hospitalized exacerbations in individuals with severe alpha-1 antitrypsin deficiency |
title | Decline in FEV(1) and hospitalized exacerbations in individuals with severe alpha-1 antitrypsin deficiency |
title_full | Decline in FEV(1) and hospitalized exacerbations in individuals with severe alpha-1 antitrypsin deficiency |
title_fullStr | Decline in FEV(1) and hospitalized exacerbations in individuals with severe alpha-1 antitrypsin deficiency |
title_full_unstemmed | Decline in FEV(1) and hospitalized exacerbations in individuals with severe alpha-1 antitrypsin deficiency |
title_short | Decline in FEV(1) and hospitalized exacerbations in individuals with severe alpha-1 antitrypsin deficiency |
title_sort | decline in fev(1) and hospitalized exacerbations in individuals with severe alpha-1 antitrypsin deficiency |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536893/ https://www.ncbi.nlm.nih.gov/pubmed/31213789 http://dx.doi.org/10.2147/COPD.S195847 |
work_keys_str_mv | AT hilleradrianamaria declineinfev1andhospitalizedexacerbationsinindividualswithseverealpha1antitrypsindeficiency AT piitulaineneeva declineinfev1andhospitalizedexacerbationsinindividualswithseverealpha1antitrypsindeficiency AT jehpssonlars declineinfev1andhospitalizedexacerbationsinindividualswithseverealpha1antitrypsindeficiency AT tanashhanan declineinfev1andhospitalizedexacerbationsinindividualswithseverealpha1antitrypsindeficiency |